14 Results

People

  1. Palomba
    Palomba
  2. Batlevi
    Batlevi
  3. Hamlin
    Hamlin
  4. Horwitz
    Horwitz
  5. Intlekofer
    Intlekofer
  6. Kumar
    Kumar
  7. Noy
    Noy
  8. Zelenetz
    Zelenetz
  9. Caron
    Caron
  10. Matasar
    Matasar

Groups

  1. Bone Marrow Transplant (14)
  2. Center for Hematologic Malignancies (14)
  3. Department of Medicine (14)
  4. GSK Faculty (14)
  5. Hematologic Malignancies Research (14)
  6. Hematologic Malignancies, Division of (14)
  7. Lymphoma (14)
  8. Population Sciences Research Program (14)
  9. Survivorship Research (14)
  10. Human Oncology and Pathogenesis Program (11)
  1. "Bone Marrow Transplant"
  2. "Center for Hematologic Malignancies"
  3. "Hematologic Malignancies Research"
  4. "Population Sciences Research Program"
  5. "Maria Palomba"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (1)
Groups
  1. Bone Marrow Transplant (14)
  2. Center for Hematologic Malignancies (14)
  3. Department of Medicine (14)
  4. GSK Faculty (14)
  5. Hematologic Malignancies Research (14)
  6. Hematologic Malignancies, Division of (14)

More Groups

People
  1. Maria Palomba (14)
  2. Connie Batlevi (12)
  3. Andrew Intlekofer (11)
  4. Andrew Zelenetz (11)
  5. Anita Kumar (11)
  6. Ariela Noy (11)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (4)
  6. 2018 (1)

More Years

Publications
  1. Blood (10)
  2. Biology of Blood and Marrow Transplantation (1)
  3. Hematological Oncology (1)
  4. Journal of Clinical Oncology (1)
  5. Value in Health (1)
Publishers
  1. American Society of Hematology (10)
  2. American Society of Clinical Oncology (1)
  3. Elsevier Inc. (1)
  4. Elsevier Science, Inc. (1)
  5. Wiley Blackwell (1)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save